WASHINGTON – Yes, Medicare Part D has produced larger than expected savings, but it might save even more if rebates on brand drugs and biologics were statutory, according to the Health and Human Services Office of Inspector General (OIG).

WASHINGTON – Lawmakers on both sides of the biologics exclusivity issue are arguing the debate in a new forum, international trade agreements.

OncoSec Medical Inc. is a lot younger than it looks, with a pipeline that would make much older start-ups envious.

Adventrx Pharmaceuticals Inc. finds itself once again requesting a meeting with the FDA so it can make its case for lung cancer drug Exelbine.

Intercept Pharmaceuticals Inc. is looking to a $163 million collaboration agreement with Les Laboratoires Servier to help it scale the mountainous challenges involved in developing a novel diabetes drug.

All those warnings about price pressures and reimbursement woes – they didn’t come from Chicken Little. The sky really could be falling for drugmakers that insist on pricing their products based on what the market used to bear. Rather than making the same old arguments about the cost of drug development, biopharma needs to understand that today’s market simply can’t bear the prices of yesterday’s bestsellers. Yes, a lot of factors are involved in drug pricing, and a lot of middle men add to the costs here in the U.S. But when it comes finger-pointing time, drugmakers tend to be...

Like their big pharma cousins, major generic drugmakers are wasting no time in hitting the biosimilar highway.

WASHINGTON – Fears that the FDA and National Institutes of Health (NIH) may loosen researchers' collars on conflicts of interest have government watchdogs nipping at their heels.

From big pharma to start-ups, companies are customizing their vehicles for the biosimilar road trip.

WASHINGTON – Immunosyn Corp.'s statements in public filings over the past few years have landed the biotech, its shareholders and senior executives on the wrong side of the SEC.